Skip to Main Content
Wexler Boley & Elgersma LLP
  • Our Firm
    • Who We Serve
      • Shareholders
      • Whistleblowers
      • Consumers
      • Businesses
      • Government Entities
    • Our Professionals
    • Working with Wexler Boley & Elgersma LLP
    • Locations
    • News
    • Careers
    • Report Your Concern
    • Testimonials
  • Practice Areas
    • Antitrust Litigation
    • Business & Commercial Litigation
    • Securities & Corporate Governance
    • Healthcare Litigation
    • Consumer Protection
    • Whistle Blower False Claims Litigation
    • Government Representation
    • Employment Litigation
  • Cases
    • Antitrust Litigation Cases
    • Business & Commercial Litigation Cases
    • Consumer Protection Cases
    • Employment Litigation Cases
    • Government Representation Cases
    • Healthcare Litigation Cases
    • Mass Tort Litigation Cases
    • Securities & Corporate Governance Cases
    • Whistle Blower False Claims Cases
  • Investigations
    • Similac Toxic Infant Formula Lawsuit
    • Kid’s Castle Biometric Privacy Lawsuit
    • Contaminated Baby Food Lawsuit
    • Fatal Sportmix Pet Food Recall Class Action Lawsuit
    • Claire’s Data Breach Lawsuit
    • Insurance Denial for Mental Health and Substance Abuse Treatment
    • Perpetual Sales Litigation
    • Railroad Price-Fixing Lawsuit
    • Medicare Advantage Fraud Litigation
    • Biometric Fingerprinting Litigation
  • Blog
  • Contact Us
See all news
4.14.2017

Judge Denies Defendants’ Motions for Partial Summary Judgement in Xarelto Case

There are currently thousands of Xarelto cases which have been consolidated in multidistrict litigation in the Eastern District of Louisiana. The Plaintiffs allege that they or their family members suffered severe bleeding and other injuries due to Xarelto’s allegedly defective design and inadequate warning label, among other things.

On April 13, 2017, the Louisiana federal judge overseeing this litigation denied the Defendants’ two motions for partial summary judgment. The Defendants had argued that federal law preempted some of the Plaintiffs’ claims because federal regulations prevented the manufacturer from updating labels or altering the dosage of the drug. U.S. District Judge Eldon Fallon disagreed, and found that the Defendants had not convincingly shown that federal regulations prevented the manufacturer of Xarelto from updating labels or creating more tailored dosing guidelines for Xarelto.

The first bellwether trial in the Xarelto litigation is set to start on April 24, 2017 in the U.S. District Court for the Eastern District of Louisiana. Wexler Wallace LLP is actively involved in Xarelto litigation and is reviewing claims involving people who took Xarelto and experienced severe, uncontrolled bleeding, stroke, or death. If you have suffered from any of these issues, you may have a Xarelto claim. Please contact Wexler Wallace LLP.

Share

  • Facebook
  • Twitter
  • LinkedIn
Image

311 S. Wacker Drive,
Suite 5450
Chicago, IL 60606
P_312.346.2222
F_312.346.0022

  • Our Firm
  • Practice Areas
  • Cases
  • Investigations
  • Newsroom
  • Blog
  • Contact Us
  • Sitemap
  • Privacy Statement
  • Legal Disclaimer

2022 © Wexler Boley & Elgersma LLP